DYADIC INTERNATIONAL INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $24.25K.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $0.00.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $359.74K.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $42.35K, a 63.43% decline year-over-year.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for fiscal 2025 was $24.25K, a 0.01% decline from fiscal 2024.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for fiscal 2024 was $24.25K.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for fiscal 2022 was $543.59K, a 55.81% decline from fiscal 2021.
- DYADIC INTERNATIONAL INC stock issued during period, value, stock options exercised for fiscal 2021 was $1.23M, a 381.49% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $24.25K 10-K · filed 2026-03-25 | |
| 2025-03-31 | $24.25K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $24.25K 10-K · filed 2026-03-25 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $543.59K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $359.74K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $42.35K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $1.23M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$590.00 10-Q · filed 2022-11-10 | $1.01M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $870.34K 10-Q · filed 2022-11-10 | $1.01M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-03-31 | $115.80K 10-Q · filed 2022-11-10 | $196.27K derived: sum of 4 quarters · filed 2022-11-10 |
| 2020-12-31 | $24.66K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $255.47K 10-K · filed 2022-03-29 |
| 2020-09-30 | $68.00 10-Q · filed 2021-11-10 | $452.41K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $55.74K 10-Q · filed 2021-11-10 | $631.75K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-03-31 | $175.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $221.60K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $550.19K 10-K · filed 2021-03-30 |
| 2019-09-30 | $179.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | |
| 2018-12-31 | $4.50K 10-K · filed 2020-03-30 | |
| 2017-12-31 | $1.44K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |